4//SEC Filing
Silva Paul M 4
Accession 0001209191-21-012355
CIK 0000875320other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 4:21 PM ET
Size
11.0 KB
Accession
0001209191-21-012355
Insider Transaction Report
Form 4
Silva Paul M
V.P. and Corporate Controller
Transactions
- Tax Payment
Common Stock
2021-02-17$211.75/sh−2,740$580,195→ 21,123 total - Sale
Common Stock
2021-02-18$210.05/sh−584$122,669→ 20,539 total - Sale
Common Stock
2021-02-18$211.82/sh−2,343$496,294→ 18,196 total - Sale
Common Stock
2021-02-18$212.62/sh−1,368$290,864→ 16,828 total
Holdings
- 169(indirect: By 401(k))
Common Stock
Footnotes (5)
- [F1]Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- [F2]Open market sales reported on this line occurred at a weighted average price of $210.05 (range $209.59 to $210.37).
- [F3]Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F4]Open market sales reported on this line occurred at a weighted average price of $211.82 (range $211.15 to $212.14).
- [F5]Open market sales reported on this line occurred at a weighted average price of $212.62 (range $212.15 to $213.14).
Documents
Issuer
VERTEX PHARMACEUTICALS INC / MA
CIK 0000875320
Entity typeother
Related Parties
1- filerCIK 0001446372
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 4:21 PM ET
- Size
- 11.0 KB